Get started

Friday

NUTANIX Stock AnalysisQuote: #NTNX Buy Target: $39.45 Sell Target: $42-$45 Panic/Exit price in case of decline and risk of being trapped= $35.00 Description: Nutanix, Inc., together with its subsidiaries, develops and provides an enterprise cloud platform in North America, Europe, the Asia Pacific, the Middle East, Latin America, and Africa. Its solution addresses a range of workloads, including enterprise applications, databases, virtual desktop infrastructure, unified communications, and big data analytics. The company offers Acropolis, an open platform comprising hyper-convergence, native virtualization, enterprise storage, virtual networking, and platform services; and Prism, an end-to-end consumer-grade management plane providing management and analytics across its software products and services. Next earnings: 05/23/2019 (NASDAQ estimate) Short Interest: Short Percent of Float 6.12 % Short % Increase / Decrease -9 % Analyst ratings: Stock Price Target NTNX High $63.00 Median $48.50 Low $25.00 Average $46.80 Current Price $39.02 March - 22 - 19 Reiterated Maxim Group Buy $62 --- $58 March - 11 - 19 Upgrade Jefferies Hold --- Buy $42 Mar-04-19 Downgrade Raymond James Outperform --- Mkt Perform Mar-01-19 Reiterated Needham Buy $76 --- $63 Mar-01-19 Reiterated Maxim Group Buy $72 --- $62 Mar-01-19 Reiterated BofA/Merrill Buy $63 --- $51 Mar-01-19 Downgrade Wells Fargo Outperform --- Market Perform $70 --- $45 Mar-01-19 Downgrade Stifel Buy --- Hold $55 --- $39 Jan-16-19 Upgrade Morgan Stanley Equal-Weight --- Overweight Please Follow us on our Social Media. Please Subscribe to our newsletter to get the analysis directly to your mail. Facebook - @SFYBUofficial Twitter - @SFYBUofficial
NASDAQ:NTNXLong
by SFYBUofficial
ImmunoPrecise Antibodies Stock AnalysisQuote: #IPA/#IPATF Buy Target:$0.80/$0.60 (don’t bet the house here looking for a quick scalp) Sell Target: $1.00 Description: ImmunoPrecise Antibodies Ltd. engages in antibody production and related services in the United States, Canada, and Europe. It also provides human antibody development, hybridoma development, genetic immunization, rabbit monoclonal antibody development, recombinant protein expression and production, cryostorage, hybridoma sequencing, antibody generation, antibody purification, polyclonal development, and peptide production services. The company has a collaboration agreement with TetraGenetics, Inc. The company was founded in 1989 and is based in Victoria, Canada. Please follow us on our facebook and twitter. Subscribe to our newsletter to get analysis directly to your mail. Facebook - @SFYBUofficial Twitter - @SFYBUoffical
ILong
by SFYBUofficial